| Aug 8 |
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
|
| Jul 30 |
Ovid Therapeutics to Present at Upcoming August Investor Conferences
|
| Jul 23 |
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
|
| Jul 15 |
Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds?
|
| Jul 10 |
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
|
| Jul 1 |
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
|
| Jun 20 |
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
|
| Jun 18 |
Oppenheimer cuts Ovid to perform, cites uncertainty over lead drug
|
| Jun 18 |
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
|
